The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations

Laura Panattoni, Tracy A. Lieu, Jinani Jayasekera, Suzanne O’Neill, Jeanne S. Mandelblatt, Ruth Etzioni, Charles E. Phelps, Scott D. Ramsey

Research output: Contribution to journalArticle

Abstract

Purpose: Little is known about whether gene expression profile (GEP) testing and specific recurrence scores (e.g., medium risk) improve women’s confidence in their chemotherapy decision or perceived recurrence risk. We evaluate the relationship between these outcomes and GEP testing. Methods: We surveyed women eligible for GEP testing (stage I or II, Gr1-2, ER+, HER2−) identified through the Surveillance, Epidemiology, and End Results (SEER) Registry of Washington or Kaiser Permanente Northern California from 2012 to 2016, approximately 0–4 years from diagnosis (N = 904, RR = 45.4%). Confidence in chemotherapy was measured as confident (Very, completely) versus Not Confident (Somewhat, A little, Not At All); perceived risk recurrence was recorded numerically (0–100%). Women reported their GEP test receipt (Yes, No, Unknown) and risk recurrence score (High, Intermediate, Low, Unknown). In our analytic sample (N = 833), we propensity score weighted the three test receipt cohorts and used propensity weighted multivariable regressions to examine associations between the outcomes and the three test receipt cohorts, with receipt stratified by score. Results: 29.5% reported an unknown GEP test receipt; 86% being confident. Compared to no test receipt, an intermediate score (aOR 0.34; 95% CI 0.20–0.58), unknown score (aOR 0.09; 95% CI 0.05–0.18), and unknown test receipt (aOR 0.37; 95% CI 0.24–0.57) were less likely to report confidence. Most women greatly overestimated their recurrence risk regardless of their test receipt or score. Conclusions: GEP testing was not associated with greater confidence in chemotherapy decisions. Better communication about GEP testing and the implications for recurrence risk may improve women’s decisional confidence.

Original languageEnglish (US)
Pages (from-to)417-427
Number of pages11
JournalBreast Cancer Research and Treatment
Volume173
Issue number2
DOIs
StatePublished - Jan 30 2019
Externally publishedYes

Fingerprint

Transcriptome
Drug Therapy
Recurrence
Propensity Score
Registries
Epidemiology
Communication

Keywords

  • Breast cancer
  • Chemotherapy
  • Gene expression profile testing

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Panattoni, L., Lieu, T. A., Jayasekera, J., O’Neill, S., Mandelblatt, J. S., Etzioni, R., ... Ramsey, S. D. (2019). The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations. Breast Cancer Research and Treatment, 173(2), 417-427. https://doi.org/10.1007/s10549-018-4988-3

The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations. / Panattoni, Laura; Lieu, Tracy A.; Jayasekera, Jinani; O’Neill, Suzanne; Mandelblatt, Jeanne S.; Etzioni, Ruth; Phelps, Charles E.; Ramsey, Scott D.

In: Breast Cancer Research and Treatment, Vol. 173, No. 2, 30.01.2019, p. 417-427.

Research output: Contribution to journalArticle

Panattoni, L, Lieu, TA, Jayasekera, J, O’Neill, S, Mandelblatt, JS, Etzioni, R, Phelps, CE & Ramsey, SD 2019, 'The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations', Breast Cancer Research and Treatment, vol. 173, no. 2, pp. 417-427. https://doi.org/10.1007/s10549-018-4988-3
Panattoni, Laura ; Lieu, Tracy A. ; Jayasekera, Jinani ; O’Neill, Suzanne ; Mandelblatt, Jeanne S. ; Etzioni, Ruth ; Phelps, Charles E. ; Ramsey, Scott D. / The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations. In: Breast Cancer Research and Treatment. 2019 ; Vol. 173, No. 2. pp. 417-427.
@article{a72bd6104440441599d5f82a22d4dcd6,
title = "The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations",
abstract = "Purpose: Little is known about whether gene expression profile (GEP) testing and specific recurrence scores (e.g., medium risk) improve women’s confidence in their chemotherapy decision or perceived recurrence risk. We evaluate the relationship between these outcomes and GEP testing. Methods: We surveyed women eligible for GEP testing (stage I or II, Gr1-2, ER+, HER2−) identified through the Surveillance, Epidemiology, and End Results (SEER) Registry of Washington or Kaiser Permanente Northern California from 2012 to 2016, approximately 0–4 years from diagnosis (N = 904, RR = 45.4{\%}). Confidence in chemotherapy was measured as confident (Very, completely) versus Not Confident (Somewhat, A little, Not At All); perceived risk recurrence was recorded numerically (0–100{\%}). Women reported their GEP test receipt (Yes, No, Unknown) and risk recurrence score (High, Intermediate, Low, Unknown). In our analytic sample (N = 833), we propensity score weighted the three test receipt cohorts and used propensity weighted multivariable regressions to examine associations between the outcomes and the three test receipt cohorts, with receipt stratified by score. Results: 29.5{\%} reported an unknown GEP test receipt; 86{\%} being confident. Compared to no test receipt, an intermediate score (aOR 0.34; 95{\%} CI 0.20–0.58), unknown score (aOR 0.09; 95{\%} CI 0.05–0.18), and unknown test receipt (aOR 0.37; 95{\%} CI 0.24–0.57) were less likely to report confidence. Most women greatly overestimated their recurrence risk regardless of their test receipt or score. Conclusions: GEP testing was not associated with greater confidence in chemotherapy decisions. Better communication about GEP testing and the implications for recurrence risk may improve women’s decisional confidence.",
keywords = "Breast cancer, Chemotherapy, Gene expression profile testing",
author = "Laura Panattoni and Lieu, {Tracy A.} and Jinani Jayasekera and Suzanne O’Neill and Mandelblatt, {Jeanne S.} and Ruth Etzioni and Phelps, {Charles E.} and Ramsey, {Scott D.}",
year = "2019",
month = "1",
day = "30",
doi = "10.1007/s10549-018-4988-3",
language = "English (US)",
volume = "173",
pages = "417--427",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations

AU - Panattoni, Laura

AU - Lieu, Tracy A.

AU - Jayasekera, Jinani

AU - O’Neill, Suzanne

AU - Mandelblatt, Jeanne S.

AU - Etzioni, Ruth

AU - Phelps, Charles E.

AU - Ramsey, Scott D.

PY - 2019/1/30

Y1 - 2019/1/30

N2 - Purpose: Little is known about whether gene expression profile (GEP) testing and specific recurrence scores (e.g., medium risk) improve women’s confidence in their chemotherapy decision or perceived recurrence risk. We evaluate the relationship between these outcomes and GEP testing. Methods: We surveyed women eligible for GEP testing (stage I or II, Gr1-2, ER+, HER2−) identified through the Surveillance, Epidemiology, and End Results (SEER) Registry of Washington or Kaiser Permanente Northern California from 2012 to 2016, approximately 0–4 years from diagnosis (N = 904, RR = 45.4%). Confidence in chemotherapy was measured as confident (Very, completely) versus Not Confident (Somewhat, A little, Not At All); perceived risk recurrence was recorded numerically (0–100%). Women reported their GEP test receipt (Yes, No, Unknown) and risk recurrence score (High, Intermediate, Low, Unknown). In our analytic sample (N = 833), we propensity score weighted the three test receipt cohorts and used propensity weighted multivariable regressions to examine associations between the outcomes and the three test receipt cohorts, with receipt stratified by score. Results: 29.5% reported an unknown GEP test receipt; 86% being confident. Compared to no test receipt, an intermediate score (aOR 0.34; 95% CI 0.20–0.58), unknown score (aOR 0.09; 95% CI 0.05–0.18), and unknown test receipt (aOR 0.37; 95% CI 0.24–0.57) were less likely to report confidence. Most women greatly overestimated their recurrence risk regardless of their test receipt or score. Conclusions: GEP testing was not associated with greater confidence in chemotherapy decisions. Better communication about GEP testing and the implications for recurrence risk may improve women’s decisional confidence.

AB - Purpose: Little is known about whether gene expression profile (GEP) testing and specific recurrence scores (e.g., medium risk) improve women’s confidence in their chemotherapy decision or perceived recurrence risk. We evaluate the relationship between these outcomes and GEP testing. Methods: We surveyed women eligible for GEP testing (stage I or II, Gr1-2, ER+, HER2−) identified through the Surveillance, Epidemiology, and End Results (SEER) Registry of Washington or Kaiser Permanente Northern California from 2012 to 2016, approximately 0–4 years from diagnosis (N = 904, RR = 45.4%). Confidence in chemotherapy was measured as confident (Very, completely) versus Not Confident (Somewhat, A little, Not At All); perceived risk recurrence was recorded numerically (0–100%). Women reported their GEP test receipt (Yes, No, Unknown) and risk recurrence score (High, Intermediate, Low, Unknown). In our analytic sample (N = 833), we propensity score weighted the three test receipt cohorts and used propensity weighted multivariable regressions to examine associations between the outcomes and the three test receipt cohorts, with receipt stratified by score. Results: 29.5% reported an unknown GEP test receipt; 86% being confident. Compared to no test receipt, an intermediate score (aOR 0.34; 95% CI 0.20–0.58), unknown score (aOR 0.09; 95% CI 0.05–0.18), and unknown test receipt (aOR 0.37; 95% CI 0.24–0.57) were less likely to report confidence. Most women greatly overestimated their recurrence risk regardless of their test receipt or score. Conclusions: GEP testing was not associated with greater confidence in chemotherapy decisions. Better communication about GEP testing and the implications for recurrence risk may improve women’s decisional confidence.

KW - Breast cancer

KW - Chemotherapy

KW - Gene expression profile testing

UR - http://www.scopus.com/inward/record.url?scp=85055435131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055435131&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-4988-3

DO - 10.1007/s10549-018-4988-3

M3 - Article

VL - 173

SP - 417

EP - 427

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -